Cellestia awarded Innosuisse Grant to advance GvHD prevention therapy

Cellestia  is proud to announce its selection for a CHF 2 million grant from the Swiss Innovation Agency, Innosuisse, as part of their Start-up Innovation project to advance to clinical Proof of Concept a first-in-class therapy for prevention of Graft vs Host Disease (GvHD).

The project aims at developing CB-103 as first-in-class drug to prevent GvHD in allogeneic-Hematopoetic Stem Cell Transplant (HSCT) patients. With this novel approach, Cellestia envisions a transformative shift in the management of GvHD from treatment to prevention.

To read the Press Release click here


No previous newsNo next news